the aid library

LIST OPTIONS

Filter

3154

Руководство по самотестированию на ВИЧ и информированию партнеров - Дополнение к сводному руководству по услугам тестирования на ВИЧ

Всемирная организация здравоохранения Всемирная организация здравоохранения (Европа); European Centre for Disease Prevention and Control (ECDC) (2018) C_WHO

ДОПОЛНЕНИЕ СЛУГИ ТЕСТИРОВАНИЯ НА ВИЧ ДЕКАБРЬ 2016 г.

САМОТЕСТИРОВАНИЮ НА ВИЧ И ИНФОРМИРОВАНИЮ ПАРТНЕРОВ

Всемирная организация здравоохранения (ВОЗ) Всемирная организация здравоохранения (ВОЗ) (2018) C_WHO

РУКОВОДСТВО ПО ДОПОЛНЕНИЕ К СВОДНОМУ РУКОВОДСТВУ ПО УСЛУГАМ ТЕСТИРОВАНИЯ НА ВИЧ ДЕКАБРЬ 2016 г. УСЛУГИ ТЕСТИРОВАНИЯ НА ВИЧ

External Link

The global distribution of lymphatic filariasis, 2000–2018: a geospatial analysis

The Lancet Global Health (2020) C1

Lymphatic filariasis is a neglected tropical disease that can cause permanent disability through disruption of the lymphatic system. This disease is caused by parasitic filarial worms that are transmitted by mosquitos. Mass drug administration (MDA) of antihelmintics is recommended by WHO to elimina... more

Multi-Sector Nutrition Education and Communication Strategy (NECS) II 2021-2025

Government of Malawi; Department of Nutrition; HIV and AIDS Ministry of Health (2021) CC2

The Department of Nutrition, HIV and AIDS (DNHA) in Ministry of Health and Population is grateful to all stakeholders who contributed to the development of the Nutrition Education Communication Strategy II. The DNHA acknowledges the financial and technical support from the World Bank and USAID throu... more

Download (197)

View PDF (488)

Turkey Syrian Refugee Resilience Plan 2020-2021
recommended

Food and Agriculture Organization of the United Nations (FAO) (2021) C1

Download (260)

View PDF (408)

WASH and the Neglected Tropical Diseases (MOZAMBIQUE)

Ogden Stephanie et al (2013) C1

This manual is intended to enable WASH practitioners who work in Mozambique to contribute to the reduction of WASH-preventable NTDs.

Download (132)

View PDF (195)

J12. Wellbeing: identification and prevention of burnout, depression and suicide among child mental health clinicians

Frances Javier, Julie Chilton & Andrés Martin IACAPAP (2015) C1

Download (116)

View PDF (139)

Cities ending the AIDS epidemic

Fast-Track Cities; UNAIDS (Joint United Nations Programme on HIVAIDS); Mairie de Paris; et al. (2016) C2

UNAIDS / 2016

Medical certification, ICD mortality coding, and reporting mortality associated with COVID-19

World Health Organization WHO (2020) C1

This technical note describes medical certification of cause of death and classification (International Classification of Diseases [ICD] mortality coding) of deaths related to COVID-19. The primary goal is to identify all deaths due to COVID-19 in all countries, including those not yet following WHO... more

Download (228)

View PDF (270)

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended

World Health Organization WHO (2022) C_WHO

This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi... more

Download (195)

View PDF (230)

Climate Change, Health, and Equity: A Guide For Local Health Departments

Rudolf,L-; C. Harrison et al. Public Health Institute (2018) CC

This 400 page guide, created by PHI’s Center for Climate Change and Health and the American Public Health Association (APHA), with support from the California Department of Public Health helps local health departments prepare for and mitigate climate change effects—from drought and heat to flood... more

Download (286)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more